Table 1 Baseline clinicopathological features of patients with ccRCC in TCGA and ICGC
Variables | TCGA cohort | ICGC cohort (n = 83) | ||||||
|---|---|---|---|---|---|---|---|---|
Training cohort (n = 242) | Validation cohort (n = 241) | Total (n = 483) | ||||||
Age, n, % | ||||||||
 <  = 65 | 157 | 64.88% | 162 | 67.22% | 319 | 66.05% | 57 | 68.67% |
 > 65 | 85 | 35.12% | 79 | 32.78% | 164 | 33.95% | 26 | 31.33% |
Gender, n, % | ||||||||
Male | 76 | 31.40% | 86 | 35.68% | 162 | 33.54% | 39 | 46.99% |
Female | 166 | 68.60% | 155 | 64.32% | 321 | 66.46% | 44 | 53.01% |
T | ||||||||
r | 145 | 59.92% | 160 | 66.39% | 305 | 63.15% | 61 | 73.49% |
T3 / T4 | 97 | 40.08% | 81 | 33.61% | 175 | 36.23% | 22 | 26.51% |
M | ||||||||
M0 | 202 | 83.47% | 204 | 84.65% | 406 | 84.06% | 75 | 90.36% |
M1 | 40 | 16.53% | 37 | 15.35% | 77 | 15.94% | 8 | 9.64% |
Stage, n, % | ||||||||
Stage I / Stage II | 134 | 55.37% | 154 | 63.90% | 288 | 59.63% | 60 | 72.29% |
Stage III / Stage IV | 108 | 44.63% | 87 | 36.10% | 195 | 40.37% | 23 | 27.71% |